Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Barring IT index all the sectoral indices on the NSE were traded in green.
At 09:25 IST, the barometer index, the S&P BSE Sensex fell 9.64 points or 0.02% to 77,134.48. The Nifty 50 index rose 2 points or 0.01% to 24,088.75.
The broader market outperformed the headline indices. The BSE 150 MidCap Index gained 0.12% and the BSE 250 SmallCap Index added 0.49%.
The market breadth was strong. On the BSE, 1,976 shares rose and 930 shares fell. A total of 190 shares were unchanged.
Foreign portfolio investors (FPIs) sold shares worth Rs 101.59 crore, while domestic institutional investors (DIIs) were net buyers to the tune of Rs 1,561.40 crore in the Indian equity market on 17 June 2026, provisional data showed.
Numbers to Track:
The yield on India's 10-year benchmark federal paper rose 0.10% to 6.872 compared with previous session close of 6.865.
In the foreign exchange market, the rupee edged lower against the dollar. The partially convertible rupee was hovering at 94.6275 compared with its close of 94.5000 during the previous trading session.
MCX Gold futures for 5 August 2026 settlement fell 0.81% to Rs 152,639.
The US Dollar Index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.15% to 100.24.
The United States 10-year bond yield declined 0.20% to 4.448.
In the commodities market, Brent crude for August 2026 settlement fell $ 1.28 or 1.61% to $78.27 a barrel.
Stocks in Spotlight:
HFCL rallied 3.23% after the company has received a contract worth Rs 2,666.09 crore from Rail Vikas Nigam (RVNL) for the execution of the BharatNet Phase-III project in Uttar Pradesh. The scope of the contract includes the supply of telecom equipment and related accessories, the creation of an optical fiber cable telecom network, and maintenance of the project for 10 years.
Lupin rose 0.93%. The company announced the launch of Azilsartan Medoxomil Tablets, 40 mg and 80 mg, in the United States following approval from the US Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA). The product is bioequivalent to Edarbi and is indicated for the treatment of hypertension in adults. Lupin is the exclusive first-to-file applicant for the generic version and is eligible for 180 days of generic drug exclusivity in the U.S. market.
Balkrishna Industries shed 0.88%. The company announced the appointment of Saroj Kumar Khuntia as chief financial officer (CFO) and key managerial personnel (KMP) with effect from 18 June 2026. Meanwhile, Madhusudan Bajaj has ceased to be the company's CFO and KMP upon attaining the age of superannuation.
Global Markets:
Asian markets traded mixed on Thursday as the US Federal Reserve indicated the possibility of a rate hike this year.
Wednesday marked the first meeting of the Federal Reserve with Kevin Warsh at the helm of the U.S. central bank. At the conclusion of the meeting, the Fed kept the benchmark federal funds rate unchanged and anchored in a range of between 3.5% and 3.75%.
Policymakers’ 'dot plot” revealed that several Fed officials now see interest rates increasing in 2026. The median estimate for the year-end interest rate now stands at 3.8%, up from 3.4% in prior projections from March, suggesting that at least one rate hike could be in the picture in 2026.
Complicating the forecast was Warsh’s decision to abstain from submitting a rate forecast.
Overnight on Wall Street, stocks fell on Wednesday, while Treasury yields surged, as investors grew uncertain over the path of monetary policy after several Federal Reserve officials indicated there could be a rate hike this year to tamp down on inflation.
The Dow Jones Industrial Average fell 507.12 points, or 0.98%, after earlier hitting a fresh all-time intraday record — the index’s third consecutive high. The 30-stock index closed at 51,492.55. The S&P 500 lost 1.21% and ended at 7,420.10. The Nasdaq Composite shed 1.34% and settled at 26,021.66.
Lupin said it is the exclusive first-to-file applicant for the product and is eligible for 180 days of generic drug exclusivity in the US market.
According to IQVIA MAT April 2026 data, Azilsartan Medoxomil Tablets had estimated annual sales of USD 53.5 million in the United States.
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients across multiple therapeutic segments. The company’s consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company’s consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.
Shares of Lupin shed 0.91% to close at Rs 2,256.25 on the BSE.
The inhaler is indicated for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Spain.
The pressurised metered dose inhaler (pMDI) combines Lupin’s respiratory expertise and manufacturing capabilities with ERN’s established distribution network and customer relationships in the Spanish market.
The collaboration marks a step forward in expanding access to respiratory care solutions in Europe, leveraging Lupin’s global inhalation portfolio and ERN’s local market presence to strengthen patient reach in Spain.
Thierry Volle, President EMEA and Emerging Markets, Lupin said, “The launch of Luforbec in Spain, following successful introductions in the UK and Germany, represents a key milestone in our partnership with ERN and reinforces our commitment to advancing global access to quality respiratory care. Together, we are building something truly exciting for patients and healthcare professionals.”
“Partnering with Lupin allows us to bring a proven, high value respiratory therapy to Spanish patients and healthcare professionals. It represents an opportunity for ERN to expand into a new therapeutic area,” said David Solanes, CEO of LABORATORIOS ERN, S.A.
Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments.
Consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25.
Shares of Lupin rose 0.12% to Rs 2,270.75 on the BSE.
Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec® (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain.
This collaboration combines Lupin's global respiratory expertise and proven pMDI manufacturing excellence and ERN's robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.
Ranluspec is the only interchangeable biosimilar ranibizumab approved in the United States in both vials and pre-filled syringes (PFS). Both the vial and PFS presentations are approved in both strengths available for Lucentis, 0.3 mg (0.05 mL of 6 mg/mL), and 0.5 mg (0.05 mL of 10 mg/mL).
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds and inhibits vascular endothelial growth factor A. It is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization.
Vinita Gupta, CEO, Lupin, said, “As our second U.S. biosimilar Ranibizumab adds depth to our biosimilars portfolio, reflecting our progress in complex biologics while expanding patient access to proven vision therapies.”
Dr. Cyrus Karkaria, President Biotechnology, Lupin., said, “The U.S. FDA approval of our biosimilar ranibizumab underscores our scientific expertise in biologics development and manufacturing, and reinforces our commitment to expanding access to advanced, affordable therapies for patients worldwide.”
Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco's Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials.
Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent to the reference listed drug (RLD) Halaven® Injection of Eisai, Inc.
Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.
Lupin today announced that it has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices, underscoring the company's strong commitment to sustainable, responsible, and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index.
The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. Lupin was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.
The Dow Jones Best-in-Class Indices recognize companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces Lupin's credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.